UA106890C2 - Гуманізоване антитіло до cdcp1 - Google Patents
Гуманізоване антитіло до cdcp1Info
- Publication number
- UA106890C2 UA106890C2 UAA201203442A UAA201203442A UA106890C2 UA 106890 C2 UA106890 C2 UA 106890C2 UA A201203442 A UAA201203442 A UA A201203442A UA A201203442 A UAA201203442 A UA A201203442A UA 106890 C2 UA106890 C2 UA 106890C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cdcp1
- libreofficeantibody
- antibody
- human cdcp1
- applying
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Винахід належить до гуманізованого антитіла до людського CDCP1, способу його одержання, фармацевтичної композиції, що містить антитіло, та застосування антитіла до людського CDCP1 при лікуванні раку.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09011046 | 2009-08-28 | ||
EP10000972 | 2010-02-01 | ||
PCT/EP2010/005244 WO2011023389A1 (en) | 2009-08-28 | 2010-08-26 | Humanized anti-cdcp1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
UA106890C2 true UA106890C2 (uk) | 2014-10-27 |
Family
ID=43086176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201203442A UA106890C2 (uk) | 2009-08-28 | 2010-08-26 | Гуманізоване антитіло до cdcp1 |
Country Status (24)
Country | Link |
---|---|
US (2) | US8394928B2 (uk) |
EP (1) | EP2470567A1 (uk) |
JP (1) | JP5647687B2 (uk) |
KR (1) | KR101495407B1 (uk) |
CN (1) | CN102482357B (uk) |
AR (1) | AR077973A1 (uk) |
AU (1) | AU2010288879A1 (uk) |
BR (1) | BR112012004221A2 (uk) |
CA (1) | CA2770161A1 (uk) |
CL (1) | CL2012000524A1 (uk) |
CO (1) | CO6511201A2 (uk) |
CR (1) | CR20120038A (uk) |
EC (1) | ECSP12011701A (uk) |
HK (1) | HK1167412A1 (uk) |
IL (1) | IL217919A0 (uk) |
MA (1) | MA33537B1 (uk) |
MX (1) | MX2012002458A (uk) |
NZ (1) | NZ597664A (uk) |
PE (1) | PE20121063A1 (uk) |
RU (1) | RU2571207C2 (uk) |
SG (1) | SG178886A1 (uk) |
TW (1) | TWI412375B (uk) |
UA (1) | UA106890C2 (uk) |
WO (1) | WO2011023389A1 (uk) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201113037A (en) * | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
TWI412375B (zh) * | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
RU2013139267A (ru) | 2011-02-10 | 2015-03-20 | Рош Гликарт Аг | Улучшенная иммунотерапия |
ES2700978T3 (es) | 2012-08-07 | 2019-02-20 | Roche Glycart Ag | Composición que comprende dos anticuerpos genomanipulados para que tengan una función efectora reducida e incrementada |
WO2014093396A1 (en) | 2012-12-10 | 2014-06-19 | Biogen Idec Ma Inc. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
WO2014172448A2 (en) * | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
AU2015209171B2 (en) | 2014-01-24 | 2020-08-06 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Antibodies against F glycoprotein of Hendra and Nipah viruses |
WO2015200522A2 (en) * | 2014-06-25 | 2015-12-30 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
MA50134A (fr) | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine Inc | Anticorps anti-protéine 1 contenant un domaine anti-cub (cdcp1), conjugués anticorps-médicament et leurs méthodes d'utilisation |
US10928391B2 (en) * | 2017-06-06 | 2021-02-23 | The Cleveland Clinic Foundation | CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease |
US11603412B2 (en) | 2017-10-25 | 2023-03-14 | The Regents Of The University Of California | Antibodies against CDCP1 for the treatment and detection of cancer |
JP7440509B2 (ja) * | 2018-11-09 | 2024-02-28 | ベス イスラエル デアコネス メディカル センター | Cdcp1-標的化療法 |
MX2021009119A (es) * | 2019-02-01 | 2022-01-18 | Fond Per Listituto Oncologico Di Ricerca Ior | Metodos de tratamiento contra el cancer de prostata resistente a la castracion. |
JPWO2021132427A1 (uk) | 2019-12-27 | 2021-07-01 | ||
CN117264055A (zh) * | 2022-06-14 | 2023-12-22 | 上海恒润达生生物科技股份有限公司 | 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用 |
WO2023246701A1 (zh) * | 2022-06-20 | 2023-12-28 | 四川汇宇制药股份有限公司 | 一种抗体及其用途 |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
KR20240057529A (ko) * | 2022-10-24 | 2024-05-03 | 주식회사 노벨티노빌리티 | 신규 항-cdcp1 항체 및 이의 용도 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
EP0938506B1 (en) * | 1996-07-16 | 2003-11-05 | Plückthun, Andreas, Prof. Dr. | Immunoglobulin superfamily domains and fragments with increased solubility |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
DK2270149T3 (en) | 1999-04-09 | 2016-05-09 | Kyowa Hakko Kirin Co Ltd | PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE. |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
CN1329061A (zh) | 2000-06-19 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——人g蛋白亚基9.46和编码这种多肽的多核苷酸 |
WO2002004508A1 (de) | 2000-07-07 | 2002-01-17 | Boehringer Ingelheim International Gmbh | Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4 |
NZ581474A (en) * | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
DE10242146A1 (de) * | 2002-09-04 | 2004-03-18 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen |
CA2513797C (en) | 2003-01-22 | 2016-05-03 | Glycart Biotechnology Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
PT1597367E (pt) | 2003-02-19 | 2010-09-02 | Scripps Research Inst | Antigénio glicoproteína sima 135 expresso em células tumorais humanas metastáticas |
WO2005011735A1 (en) | 2003-07-29 | 2005-02-10 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
JP2007504245A (ja) | 2003-09-05 | 2007-03-01 | ジェネンテック・インコーポレーテッド | 変更したエフェクター機能を有する抗体 |
GB0324656D0 (en) | 2003-10-22 | 2003-11-26 | Celltech R&D Ltd | A protein involved in ovarian cancer |
LT2348051T (lt) | 2003-11-05 | 2019-02-25 | Roche Glycart Ag | Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija |
US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
JP5315489B2 (ja) | 2005-04-26 | 2013-10-16 | アール クレア アンド カンパニー | エフェクター機能が増強されたヒトIgG抗体を作製する方法 |
CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
WO2007005502A2 (en) | 2005-06-30 | 2007-01-11 | Applera Corporation | Methods and compositions for treating diseases targeting cdcp1 |
US20070071745A1 (en) | 2005-08-26 | 2007-03-29 | Pablo Umana | Modified antigen binding molecules with altered cell signaling activity |
JP2007112734A (ja) | 2005-10-19 | 2007-05-10 | Chugai Pharmaceut Co Ltd | 抗cdcp1抗体を含有する癌細胞増殖抑制剤 |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
TWI412375B (zh) * | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
-
2010
- 2010-08-25 TW TW099128526A patent/TWI412375B/zh not_active IP Right Cessation
- 2010-08-26 UA UAA201203442A patent/UA106890C2/uk unknown
- 2010-08-26 BR BR112012004221A patent/BR112012004221A2/pt not_active IP Right Cessation
- 2010-08-26 PE PE2012000273A patent/PE20121063A1/es not_active Application Discontinuation
- 2010-08-26 CA CA2770161A patent/CA2770161A1/en not_active Abandoned
- 2010-08-26 MX MX2012002458A patent/MX2012002458A/es active IP Right Grant
- 2010-08-26 AR ARP100103121A patent/AR077973A1/es unknown
- 2010-08-26 KR KR1020127007820A patent/KR101495407B1/ko not_active IP Right Cessation
- 2010-08-26 US US12/868,845 patent/US8394928B2/en not_active Expired - Fee Related
- 2010-08-26 WO PCT/EP2010/005244 patent/WO2011023389A1/en active Application Filing
- 2010-08-26 EP EP10748062A patent/EP2470567A1/en not_active Withdrawn
- 2010-08-26 CN CN201080037452.7A patent/CN102482357B/zh not_active Expired - Fee Related
- 2010-08-26 RU RU2012111708/10A patent/RU2571207C2/ru not_active IP Right Cessation
- 2010-08-26 JP JP2012525932A patent/JP5647687B2/ja not_active Expired - Fee Related
- 2010-08-26 NZ NZ597664A patent/NZ597664A/xx not_active IP Right Cessation
- 2010-08-26 AU AU2010288879A patent/AU2010288879A1/en not_active Abandoned
- 2010-08-26 SG SG2012013397A patent/SG178886A1/en unknown
-
2012
- 2012-01-20 CR CR20120038A patent/CR20120038A/es unknown
- 2012-02-02 IL IL217919A patent/IL217919A0/en unknown
- 2012-02-27 MA MA34651A patent/MA33537B1/fr unknown
- 2012-02-28 EC ECSP12011701 patent/ECSP12011701A/es unknown
- 2012-02-28 CL CL2012000524A patent/CL2012000524A1/es unknown
- 2012-02-29 CO CO12035757A patent/CO6511201A2/es active IP Right Grant
- 2012-08-20 HK HK12108145.3A patent/HK1167412A1/xx not_active IP Right Cessation
- 2012-12-20 US US13/721,553 patent/US9346886B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ597664A (en) | 2013-03-28 |
US8394928B2 (en) | 2013-03-12 |
IL217919A0 (en) | 2012-03-29 |
US9346886B2 (en) | 2016-05-24 |
CR20120038A (es) | 2012-04-18 |
CA2770161A1 (en) | 2011-03-03 |
JP5647687B2 (ja) | 2015-01-07 |
CL2012000524A1 (es) | 2012-08-17 |
MX2012002458A (es) | 2012-03-14 |
MA33537B1 (fr) | 2012-08-01 |
AU2010288879A1 (en) | 2012-02-02 |
CO6511201A2 (es) | 2012-08-31 |
CN102482357B (zh) | 2014-06-11 |
ECSP12011701A (es) | 2012-03-30 |
CN102482357A (zh) | 2012-05-30 |
HK1167412A1 (en) | 2012-11-30 |
AR077973A1 (es) | 2011-10-05 |
PE20121063A1 (es) | 2012-08-09 |
JP2013502904A (ja) | 2013-01-31 |
TWI412375B (zh) | 2013-10-21 |
TW201110983A (en) | 2011-04-01 |
WO2011023389A1 (en) | 2011-03-03 |
US20110052582A1 (en) | 2011-03-03 |
US20130209455A1 (en) | 2013-08-15 |
RU2012111708A (ru) | 2013-10-10 |
KR101495407B1 (ko) | 2015-02-24 |
KR20120089658A (ko) | 2012-08-13 |
BR112012004221A2 (pt) | 2016-11-29 |
SG178886A1 (en) | 2012-04-27 |
RU2571207C2 (ru) | 2015-12-20 |
EP2470567A1 (en) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA106890C2 (uk) | Гуманізоване антитіло до cdcp1 | |
TN2015000396A1 (en) | Antibody drug conjugates | |
MX2020004503A (es) | Anticuerpos cd3 humanizados o quimericos. | |
WO2014160160A3 (en) | Antibody drug conjugates and corresponding antibodies | |
GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
MX2014009289A (es) | Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer. | |
MX2020012426A (es) | Anticuerpos anti-cd38. | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
MX341578B (es) | Tratamiento de la osteoartritis y del dolor. | |
UA101487C2 (en) | Humanized b-ly1 antibody formulation | |
CA3019531A1 (en) | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer | |
WO2013072813A3 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
MX355181B (es) | Anticuerpos humanos contra el factor tisular. | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
WO2014163714A3 (en) | Antibody drug conjugates | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
MX2015008534A (es) | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. | |
TN2015000277A1 (en) | Bmp-6 antibodies | |
SG178881A1 (en) | Antibodies against cdcp1 for the treatment of cancer | |
MX2013002718A (es) | Composiciones de anticuerpo anti-vegfr-3. |